fruquintinib + camrelizumab + capecitabine

This is a combination therapy consisting of three agents: fruquintinib (a selective VEGFR inhibitor), camrelizumab (a PD-1 inhibitor), and capecitabine (a fluoropyrimidine chemotherapy agent). While the exact combination of all three agents is not well-documented in the provided information, similar combinations have been studied. Fruquintinib is an oral multi-kinase inhibitor that selectively targets VEGFR1, VEGFR2, and VEGFR3, inhibiting angiogenesis. Camrelizumab is a PD-1 inhibitor that works by enhancing T-cell immune responses. Capecitabine is a prodrug that converts to 5-fluorouracil in tumor tissues. The combination likely aims to leverage synergistic effects between anti-angiogenic therapy, immunotherapy, and chemotherapy.